Long-term laryngeal allograft survival using low-dose everolimus

David G. Lott, Olivia Dan, Lina Lu, Marshall Strome

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Objective: The purpose of this study was to explore the mechanism and utility of everolimus as a single-agent therapy in preventing mouse laryngeal allograft rejection. Study Design: Prospective animal study. Setting: Academic research at a tertiary medical center. Subjects and Methods: Fifteen recipient mice (five per group) were injected with everolimus (1 mg/kg/d) until euthanized at 15, 30, and 60 days posttransplantation. Five mice received transplants without immunosuppression and were euthanized at day 15. Larynges were graded for rejection severity. Draining lymph nodes and spleens were evaluated by flow cytometry to assess the systemic immunological environment. Results: Each time group demonstrated minor allograft rejection (rejection severity scores: 2.51, 2.46, 2.78; no rejection, 1; severe, 6). This was not significantly different between groups. Everolimus-treated mice had significantly less rejection at all time points compared with non-immunosuppressed mice. Flow cytometry showed a blunted cytotoxic T-cell response, differentiation favoring regulatory T-cells, and decreased number and function of dendritic cells. Conclusions: Everolimus successfully prevents laryngeal allograft rejection up to 60 days posttransplantation. It appears to increase the production of regulatory T-cells while decreasing cytotoxic T-cell and dendritic cell response. Everolimus alone or in combination with other immunosuppressants may enable laryngeal transplantation to become a viable reconstructive option following laryngectomy for malignancy.

Original languageEnglish (US)
Pages (from-to)72-78
Number of pages7
JournalOtolaryngology - Head and Neck Surgery
Issue number1
StatePublished - Jan 2010

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology


Dive into the research topics of 'Long-term laryngeal allograft survival using low-dose everolimus'. Together they form a unique fingerprint.

Cite this